The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma

British Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2010, Pages 903-907

  Egerer, Gerlinde ^a   Eisenlohr, Kathrin ^b   Gronkowski, Martina ^a   Burhenne, Juergen ^b   Riedel, Klaus Dieter ^b   Mikus, Gerd ^b  

^a Oncology and Rheumatology ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aprepitant; Interaction; Melphalan

Indexed keywords

APREPITANT; MELPHALAN; PLACEBO; ALKYLATING AGENT; ANTIEMETIC AGENT; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; ADULT; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG INTERACTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; MIDDLE AGED; MORPHOLINES; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RECEPTORS, NEUROKININ-1; TRANSPLANTATION CONDITIONING;

EID: 78349244860     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03792.x     Document Type: Article

References (21)

1. Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164-8.
2. Goldschmidt H, Sonneveld P, Cremer FW, Van Der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 2003; 82: 654-9.
3. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568-73.
4. Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer 1994; 30A: 1083-8.
5. Italian Group for Antiemetic Research. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Support Care Cancer 1994; 2: 167-70.
6. De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-11.
7. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin- the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
8. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-94.
9. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24.
10. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003; 25: 1407-19.
11. TM) in human serum and plasma by automated solid phase extraction and liquid chromatography tandem mass spectrometry. Chromatographia 2000; 52: S92-S97.
12. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287-92.
13. De Jonge ME, Huitema AD, Holtkamp MJ, Van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56: 370-8.
14. Bubalo JS, Leis JF, Curtin PT, Maziarz RT, Kovascovics TJ, Meyers G, McCune JS, Munar MY, Hayes-Lattin B, Jones N. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007; 25: 9112.
15. Walko CM, Yu YA, Bhushan S, Spasojevic I, Carey L, Collichio F, Armstrong D, Dees EC. Effect of aprepitant on cyclophosphamide pharmacokinetics in early breast cancer patients. J Clin Oncol 2009; 27: 15S.
16. Loos WJ, De Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, Van Noort C, De Bruijn P, Verweij J. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007; 59: 407-12.
17. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010 May 20; [Epub ahead of print.
18. Kühne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmöller J. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 2009; 78: 45-53.
19. Feuring M, Lee Y, Orlowski LH, Michiels N, De Smet M, Majumdar AK, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hesney M, Brackett LE, Wehling M. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003; 43: 912-7.
20. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76: 73-84.
21. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-99.